GlassScriptPhysician profile
Alan Michael Hicks
NPI 1720503972
$12,445.10
in general payments reported to CMS, 2019-2025
59 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,590 · 2022: $2,357 · 2023: $2,462 · 2024: $2,966 · 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,462 · Travel and Lodging: $925 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,461.83 |
| Travel and Lodging | $925.01 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,880.46 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,225.29 | 2021-2025 | |
| Lilly USA, LLC | $1,110.58 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Stryker Corporation | $1,053.94 | 2024 | Procuity |
| Novo Nordisk INC | $1,033.42 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $822.11 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $408.41 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $355.94 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.15 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $334.45 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $284.54 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $271.86 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $236.94 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.85 | 2021-2024 | Jardiance, Stiolto Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.92 | 2022-2025 | Caplyta |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $178.58 | 2021-2024 | Veozah |
| Pfizer INC. | $174.51 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.75 | 2021-2025 | Trintellix |
| Corium, LLC | $170.46 | 2022-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $139.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $136.12 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $116.15 | 2021 | |
| Vanda Pharmaceuticals INC. | $113.39 | 2025 | Fanapt |
| Abbott Laboratories | $103.41 | 2022-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Merck Sharp & Dohme LLC | $97.14 | 2023 | Verquvo, Belsomra, Lagevrio |
| Sumitomo Pharma America, INC. | $93.25 | 2023-2024 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $77.74 | 2021-2023 | |
| Ardelyx, INC. | $77.57 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $75.86 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $70.56 | 2021-2023 | Yupelri |
| Ironshore Pharmaceuticals INC. | $62.60 | 2024 | |
| Viatris Specialty LLC | $54.65 | 2025 | Yupelri |
| Dexcom, INC. | $54.16 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $52.37 | 2022-2024 | Repatha, Otezla |
| Eisai INC. | $49.37 | 2021 | |
| Exact Sciences Corporation | $46.48 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Daiichi Sankyo INC. | $41.83 | 2021-2022 | |
| Mannkind Corporation | $38.57 | 2021 | |
| Alkermes, INC. | $37.39 | 2022-2025 | Aristada, Lybalvi |
| Aimmune Therapeutics, INC. | $32.99 | 2024 | |
| Esperion Therapeutics, INC. | $32.67 | 2022-2023 | Nexletol |
| Insulet Corporation | $30.96 | 2024 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $30.41 | 2023-2024 | Livalo, Seglentis |
| Paratek Pharmaceuticals, INC. | $26.61 | 2025 | Nuzyra |
| Noven Therapeutics, LLC | $25.82 | 2022 | |
| Forte Bio-Pharma LLC | $25.45 | 2024 | Prolate, Nalocet |
| Axsome Therapeutics, INC. | $23.65 | 2023 | Auvelity |
| Scilex Pharmaceuticals INC. | $21.91 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.97 | 2023 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $19.86 | 2021 | |
| Boston Scientific Corporation | $18.05 | 2022 | |
| Tris Pharma INC | $16.60 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $15.75 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.33 | 2022 | |
| Redhill Biopharma INC. | $15.22 | 2021 | |
| Medtronic, INC. | $14.46 | 2022 | |
| Verona Pharma, INC. | $13.75 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $13.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.